The impact of olanzapine on tardive dyskinetic symptoms in a state hospital population

Annals of Clinical Psychiatry

Volumn 20, Issue 3, 2008, Pages 139-144

  Brar, Jaspreet S ^a   Parepally, Haranath ^a   Chalasani, Lokaranjit ^b   Gopalani, Aziz ^c,d   Appel, Nicole ^a   Chengappa, K N Roy ^a,d  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d Mayview State Hospital   (United States)

Author keywords

Abnormal Involuntary Movement Scale (AIMS); Olanzapine; Schizophrenia; State hospital; Tardive dyskinesia

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; ARTICLE; BIPOLAR I DISORDER; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; SYMPTOM; TARDIVE DYSKINESIA;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; CROSS-SECTIONAL STUDIES; DYSKINESIA, DRUG-INDUCED; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 47549098624     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: 10.1080/10401230802177755     Document Type: Article

References (36)

1. Fenton WS. Prevalence of spontaneous dyskinesia in schizophrenia. J Clin Psychiatry. 2000;61:10-14.
2. Glazer WM. Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry. 2000;61:21-26.
3. Glazer WM. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry. 2000;61:15-20.
4. Woerner MG, Saltz BL, Kane JM, Lieberman JA, Alvir JM: Diabetes and development of tardive dyskinesia. Am J Psychiatry. 1993;150:966-968.
5. Kane JM, Smith JM. Tardive dyskinesia: Prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry. 1982;39:473-481.
6. Woerner MG, Kane JM, Lieberman JA, Alvir J, Bergmann KJ, Borenstein M, Schooler NR, Mukherjee S, Rotrosen J, Rubinstein M. The prevalence of tardive dyskinesia. J Clin Psychopharmacol. 1991;11:34-42.
7. Kane JM. Tardive dyskinesia rates with atypical antipsychotics in adults: Prevalence and incidence. J Clin Psychiatry. 2004;65:16-20.
8. Casey DE. Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res. 1999;35:S61-S66.
9. Cole JO, Gardos G, Tarsy D. Drug trials in persistent dyskinesia. In: Fann WE, Smith RC, Davis JM, eds. Tardive Dyskinesia Research and Treatment. New York: SP Medical and Scientific Books; 1980:419-427.
10. Gerbino L, Shopsin B, Collora M. Clozapine in the treatment of tardive dyskinesia: An interim report. In: Fann WE, Smith RC, Davis JM, eds. Tardive Dyskinesia Research and Treatment. New York: SP Medical and Scientific Books; 1980:475-489.
11. Small JG, Milstein V, Marhenke JD, Hall DD, Kellams JJ. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis. J Clin Psychiatry. 1987;48:263-267.
12. Lieberman JA, Saltz BL, Johns CA, Pollack S, Kane JM. Clozapine effects on tardive dyskinesia. Psychopharmacol Bull. 1989;25:57-62.
13. Levin H, Chengappa KN, Kambhampati RK, Mahdavi N, Ganguli R. Should chronic treatment-refractory akathisia be an indication for the use of clozapine in schizophrenic patients? J Clin Psychiatry. 1992;53:248-251.
14. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies [see comment]. Am J Psychiatry. 2004;161:414-425.
15. Almeida OP. Olanzapine for the treatment of tardive dyskinesia. J Clin Psychiatry. 1998;59:380-381.
16. Littrell KH, Johnson CG, Littrell S, Peabody CD. Marked reduction of tardive dyskinesia with olanzapine. Arch Gen Psychiatry. 1998;55:279-280.
17. Agarwal V, Kumar P. Olanzapine in the treatment of tardive dyskinesia: A report of 2 cases. J Clin Psychiatry. 2001;62:298-299.
18. Raja M, Azzoni A, Maisto G. Three cases of improvement of tardive dyskinesia following olanzapine treatment. Int J Neuropsychopharmacol. 1999;2:333-334.
19. Lykouras L, Agelopoulos E, Tzavellas E. Improvement of tardive dyskinesia following switch from neuroleptics to olanzapine. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:815-817.
20. Snoddgrass PL, Labbate LA. Tardive dyskinesia from risperidone and olanzapine in an alcoholic man. Can J Psychiatry. 1999;44:921.
21. Strous RD, Kupchik M, Roitman S, Schwartz S, Gonen N, Mester R, Weizman A, Spivak B. Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study. Hum Psychopharmacology. 2006;21:235-243.
22. Herran A, Vazquez-Barquero JL. Tardive dyskinesia associated with olanzapine. Ann Intern Med. 1999;131:72.
23. Bella VL, Piccoli F. Olanzepine-induced tardive dyskinesia. Br J Psychiatry. 2003;182:81-82.
24. Bhanji NH, Margolese HC. Tardive dyskinesia associated with olanzapine in a neuroleptic-naive patient with schizophrenia. Can J Psychiatry. 2004;49:343.
25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association; 1994.
26. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: Department of Health and Human Services; 1976.
27. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39:486-487.
28. Levine J, Chengappa KNR, Patel M, Vagnucci A, John V, Brar JS, Chalasani L, Parepally H, Ganguli R. Obesity and medical illnesses in psychiatric patients admitted to a long-term psychiatric facility. J Psych Pract. 2001;11:432-439.
29. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry. 2001;158:360-369.
30. Sakai K, Gao XM, Hashimoto T, Tamminga CA. Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal ganglia-thalamocortical neural pathways. Synapse. 2001;39:152-160.
31. Goff DC, Hennen J, Lyoo IK, Tsai G, Wald LL, Evins AE, Yurgelun-Todd DA, Renshaw PF. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biol Psychiatry. 2002;51:493-497.
32. Ichikawa J, Dai J, O'Laughlin IA, Fowler WL, Meltzer HY. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology. 2002;26:325-339.
33. Li XM, Chlan-Fourney J, Juorio AV, Bennett VL, Shrikhande S, Keegan DL, Qi J, Boulton AA. Differential effects of olanzapine on the gene expression of superoxide dismutase and the low affinity nerve growth factor receptor. J Neurosci Res. 1999;56:72-75.
34. de Jesus Mari J, Lima MS, Costa AN, Alexandrino N, Rodrigues-Filho S, de Oliveira IR, Tollefson GD. The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders. Eur Arch Psychiatry Clin Neurosci. 2004;254:356-361.
35. Kinon BJ, Jeste DV, Kollack-Walker S, Stauffer V, Liu-Seifert H. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: A prospective clinical trial with patients randomized to blinded dose reduction periods. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:985-996.
36. Sanger TM, Grundy SL, Gibson PJ, Namjoshi MA, Greaney MG, Tohen MF. Long-term olanzapine therapy in the treatment of bipolar I disorder: An open-label continuation phase study. J Clin Psychiatry. 2001;62:273-281.